Cytokinetics Inc (CYTK.OQ)
* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS
* CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018
Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.
Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.
* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints
Nov 21 Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.
* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing Source text: http://bit.ly/2hauCBo Further company coverage:
* Cytokinetics - on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015
* Cytokinetics, Inc. reports third quarter 2017 financial results
|Eisai Co., Ltd (4523.T)||¥7,151||--|
|Mitsubishi Tanabe Pharma Corp (4508.T)||¥2,078||--|
|Novartis AG (NOVN.S)||CHF76.04||-0.04|
|GlaxoSmithKline plc (GSK.L)||1,445.00||+15.00|
|Shire PLC (SHP.L)||3,800.00||-21.50|
|Shire PLC (3159084.L)||--||--|
|Acorda Therapeutics Inc (ACOR.OQ)||$23.35||0.00|
|Ionis Pharmaceuticals Inc (IONS.OQ)||$50.70||+2.19|
|Ligand Pharmaceuticals Inc. (LGND.OQ)||$167.22||+0.24|
|Neuralstem, Inc. (CUR.OQ)||$1.64||-0.02|